1. Home
  2. UCAR vs TELA Comparison

UCAR vs TELA Comparison

Compare UCAR & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo U Power Limited

UCAR

U Power Limited

HOLD

Current Price

$1.35

Market Cap

35.5M

ML Signal

HOLD

Logo TELA Bio Inc.

TELA

TELA Bio Inc.

HOLD

Current Price

$0.86

Market Cap

41.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UCAR
TELA
Founded
2013
2012
Country
China
United States
Employees
N/A
N/A
Industry
Retail-Auto Dealers and Gas Stations
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.5M
41.3M
IPO Year
2022
2019

Fundamental Metrics

Financial Performance
Metric
UCAR
TELA
Price
$1.35
$0.86
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$50.00
$2.00
AVG Volume (30 Days)
480.7K
105.0K
Earning Date
05-15-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
37.59
EPS
N/A
N/A
Revenue
N/A
$80,275,000.00
Revenue This Year
N/A
$10.23
Revenue Next Year
N/A
$14.26
P/E Ratio
N/A
N/A
Revenue Growth
N/A
15.84
52 Week Low
$0.04
$0.50
52 Week High
$4.98
$2.19

Technical Indicators

Market Signals
Indicator
UCAR
TELA
Relative Strength Index (RSI) 46.86 49.54
Support Level $1.14 $0.79
Resistance Level $1.68 $0.91
Average True Range (ATR) 0.11 0.10
MACD -0.01 -0.01
Stochastic Oscillator 22.77 36.31

Price Performance

Historical Comparison
UCAR
TELA

About UCAR U Power Limited

U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.

About TELA TELA Bio Inc.

TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.

Share on Social Networks: